KDMN News and Press, Kadmon Holdings Inc. From 12/06/20

- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively - - cGVHD Key Opinion Leader Webcast Today at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) - NEW YORK, NY / ACCESSWIRE / December 6, 2020 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced 12-mon...

Under Priority Review status, the FDA accepts Kadmon Holdings' (KDMN) marketing application seeking approval of belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of patients with chronic graft-versus-host disease.The agency's action date is May 30, 2021.S...

- FDA Grants Priority Review and Sets PDUFA Date of May 30, 2021 - - Application Being Evaluated Under FDA's Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs - NEW YORK, NY / ACCESSWIRE / November 30, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that t...

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the Company will host a virtual key opinion leader event on Sunday, December 6, 2020 at 11:15 a.m. PT (2:15 p.m. ET) at the 62 nd American Society of Hematology (ASH) Annual Meeting. ...

Dan Loeb's 13F portfolio value increased from ~$7.30B to ~$10B this quarter. The number of positions increased from 36 to 47. Third Point added PG&E while dropping Baxter International and Raytheon Technologies during the quarter. The top three positions are at ~22% of the por...

Kadmon (KDMN): Q3 GAAP EPS of -$0.15 beats by $0.02.Revenue of $0.49M (+113.0% Y/Y) beats by $0.01M.Press Release For further details see: Kadmon EPS beats by $0.02, beats on revenue

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2020. "The submission of our belumosudil New Drug Application to the FDA represents a significant achie...

NEW YORK, NY / ACCESSWIRE / November 4, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) announced today that 12-month data from ROCKstar (KD025-213), the ongoing pivotal trial of belumosudil (KD025) for the treatment of chronic graft-versus-host disease (cGVHD), have been selected for oral presen...

Kadmon (KDMN) to transfer its stock exchange listing from the New York Stock Exchange (‘NYSE’) to the Nasdaq Global Select Market ("Nasdaq").Company will retain the "KDMN" ticker with trading on the Nasdaq expected to begin on October 26, 2020. For further details see: Kad...

NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) announced today that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market ("Nasdaq"). The Company will retain the "KDMN" ticker wit...